Multivariate analysis of PM PET and MFC negativity for PFS and OS in patients treated with daratumumab
| . | HR . | 95% CI . | P value . |
|---|---|---|---|
| PFS | |||
| PM PET negativity | 0.39 | 0.19-0.80 | .01 |
| PM MFC negativity | 0.39 | 0.22-0.69 | .001 |
| R-ISS, III | 2.14 | 0.90-5.08 | .084 |
| OS | |||
| PM PET negativity | 0.29 | 0.09-0.87 | .027 |
| R-ISS, III | 5.36 | 1.91-15.05 | .001 |
| . | HR . | 95% CI . | P value . |
|---|---|---|---|
| PFS | |||
| PM PET negativity | 0.39 | 0.19-0.80 | .01 |
| PM MFC negativity | 0.39 | 0.22-0.69 | .001 |
| R-ISS, III | 2.14 | 0.90-5.08 | .084 |
| OS | |||
| PM PET negativity | 0.29 | 0.09-0.87 | .027 |
| R-ISS, III | 5.36 | 1.91-15.05 | .001 |